United Therapeutics Corp. (UTHR) Tyvaso Dry Powder Inhaler Likely to be Approved by FDA - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $275.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
